AXIM Biotech Locks Down New Medical Hemp Facility in the Netherlands

AXIM Biotechnologies, Inc. (OTC: AXIM), an innovative company focused on the research, development and production of hemp-based pharmaceutical, nutraceutical and cosmetic products with an emphasis on the well-being of their customers, announced today that it has secured the down payment on land to build a brand new, state-of-the-art facility on 6,000 square meters of land located at the industrial estate of Stichtsekant, in the city of Almere, The Netherlands. AXIM Biotech’s future high-tech factory will be located on the corner of Fort de Gagel and Fort Blauwkape.

Holding exclusive rights to the world’s first patented cannabinoid release chewing gum and, with it, plans to conduct clinical trials for pain and spasticity associated with Multiple Sclerosis (MS) set in the EU, AXIM Biotech is leading the life sciences industry with hemp-based innovations. AXIM’s focus lies in developing unique and proprietary delivery mechanisms for the introduction of cannabinoids (i.e. THC, CBD, CBG, CBN, etc.)...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.